UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Dose-response relationships for alendronate treatment in osteoporotic elderly women

The journal of clinical endocrinology and metabolism, 1997, Vol.82 (1), p.265-274

1997

Volltextzugriff (PDF)

MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism

The journal of clinical endocrinology and metabolism, 1998-02, Vol.83 (2), p.320-325

1998

Volltextzugriff (PDF)

Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure

The journal of clinical endocrinology and metabolism, 1998-02, Vol.83 (2), p.362-369

1998

Volltextzugriff (PDF)

A phase II randomized, placebo-controlled, double-blind study of the efficacy and safety of RC-1291 (RC) for the treatment of cancer cachexia

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.9133-9133

2007

Volltextzugriff (PDF)

Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/insulin-like growth factor-I axis in selected GH-deficient adults

The journal of clinical endocrinology and metabolism, 1997-10, Vol.82 (10), p.3455-3463

1997

Volltextzugriff (PDF)

Initial human experience with MK-462 (rizatriptan): a novel 5-HT1D agonist

British journal of clinical pharmacology, 1997-01, Vol.43 (1), p.49

1997

Volltextzugriff (PDF)

Zolmitriptan (311C90) does not interact with fluoxetine in healthy volunteers

International journal of clinical pharmacology and therapeutics, 1998-06, Vol.36 (6), p.301

1998

Volltextzugriff (PDF)

Treatment with the Oral Growth Hormone Secretagogue MK‐677 Increases Markers of Bone Formation and Bone Resorption in Obese Young Males

Journal of bone and mineral research, 1998-07, Vol.13 (7), p.1158-1166

1998

Volltextzugriff (PDF)

Pharmacokinetics, pharmacodynamics, and dose-response relationship of repaglinide in type 2 diabetes

Diabetes technology & therapeutics, 1999, Vol.1 (3), p.247-256

1999

Volltextzugriff (PDF)

Gastrokinetic effect of ghrelin analog RC-1139 in the rat Effect on post-operative and on morphine induced ileus

Peptides (New York, N.Y. : 1980), 2005-09, Vol.26 (9), p.1598-1601

2005

Volltextzugriff (PDF)

PHARMACOKINETICS AND FOOD INTERACTION OF MK-462 IN HEALTHY MALES

Biopharmaceutics & drug disposition, 1996-01, Vol.17 (1), p.17-24

1996

Volltextzugriff (PDF)

MK-677, an Orally Active Growth Hormone Secretagogue, Reverses Diet-Induced Catabolism1

The journal of clinical endocrinology and metabolism, 1998-02, Vol.83 (2), p.320-325

1998

Volltextzugriff (PDF)

Pharmacokinetics of extended release diltiazem in elderly subjects

American journal of hypertension, 1995-04, Vol.8 (4), p.67A-67A

1995

Volltextzugriff (PDF)

Prospects for human gene therapy

Journal of reproductive medicine, 1992-06, Vol.37 (6), p.508

1992

Volltextzugriff (PDF)

Molecular cloning and nucleotide sequence of cDNA encoding a functional murine low-density-lipoprotein receptor

Somatic cell and molecular genetics, 1992-09, Vol.18 (5), p.443-450

1992

Volltextzugriff (PDF)

Prolonged fenoldopam infusions in patients with mild to moderate hypertension: Pharmacodynamic and pharmacokinetic effects

American journal of hypertension, 1999-09, Vol.12 (9), p.906-914

1999

Volltextzugriff (PDF)

Two-Month Treatment of Obese Subjects with the Oral Growth Hormone (GH) Secretagogue MK-677 Increases GH Secretion, Fat-Free Mass, and Energy Expenditure1

The journal of clinical endocrinology and metabolism, 1998-02, Vol.83 (2), p.362-369

1998

Volltextzugriff (PDF)

Two-Month Treatment of Obese Subjects with the Oral Growth Hormone (GH) Secretagogue MK-677 Increases GH Secretion, Fat-Free Mass, and Energy Expenditure 1

The journal of clinical endocrinology and metabolism, 1998-02, Vol.83 (2), p.362-369

1998

Volltextzugriff (PDF)

Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers

The journal of clinical endocrinology and metabolism, 1997-01, Vol.82 (1), p.265

1997

Volltextzugriff (PDF)

Initial human experience with MK-462 (rizatriptan) : a novel 5-HT ID agonist

British journal of clinical pharmacology, 1997, Vol.43 (1), p.49-54

1997

Volltextzugriff (PDF)

Reformulations Must Provide Added Value: Novel Drugs Must Really Improve on the Original; Dosing Convenience Alone Is Not Enough

Genetic engineering & biotechnology news, 2012-02, Vol.32 (4), p.36-37

Polvino, William

2012

Volltextzugriff (PDF)

D5Effect Of Food On The Pharmacokinetics Of Extended Release Diltiazem

American journal of hypertension, 1995-04, Vol.8 (4-Pt-2), p.68A-68A

1995

Volltextzugriff (PDF)

D4Pharmacokinetics Of Extended Release Diltiazem In Elderly Subjects

American journal of hypertension, 1995-04, Vol.8 (4-Pt-2), p.67A-67A

1995

Volltextzugriff (PDF)

Effect of food on the pharmacokinetics of extended release diltiazem

American journal of hypertension, 1995-04, Vol.8 (4), p.68A-68A

1995

Volltextzugriff (PDF)

Improved protein analysis on nitrocellulose membranes

Electrophoresis, 1983-02, Vol.4 (5), p.368-369

1983

Volltextzugriff (PDF)

1 – 25 von 33

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(30)
Mit Volltextzugriff
(30)

Publikationsform

Sprache

Englisch
(33)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(18)
Life Sciences & Biomedicine
(17)
Biological And Medical Sciences
(13)
Humans
(11)
Adult
(9)
Double-Blind Method
(9)
Male
(9)
Medical Sciences
(8)
Pharmacology. Drug Treatments
(7)
Endocrinology & Metabolism
(6)
Middle Aged
(6)
Animals
(5)
Biochemistry & Molecular Biology
(5)
Female
(5)
Fundamental And Applied Biological Sciences. Psychology
(5)
Administration, Oral
(4)
Adolescent
(4)
Dose-Response Relationship, Drug
(4)
Mice
(4)
Pharmacokinetics
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Dose-response relationships for alendronate treatment in osteoporotic elderly women

MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism

Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure

A phase II randomized, placebo-controlled, double-blind study of the efficacy and safety of RC-1291 (RC) for the treatment of cancer cachexia

Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/insulin-like growth factor-I axis in selected GH-deficient adults

Initial human experience with MK-462 (rizatriptan): a novel 5-HT1D agonist

Zolmitriptan (311C90) does not interact with fluoxetine in healthy volunteers

Treatment with the Oral Growth Hormone Secretagogue MK‐677 Increases Markers of Bone Formation and Bone Resorption in Obese Young Males

Pharmacokinetics, pharmacodynamics, and dose-response relationship of repaglinide in type 2 diabetes

Gastrokinetic effect of ghrelin analog RC-1139 in the rat Effect on post-operative and on morphine induced ileus

PHARMACOKINETICS AND FOOD INTERACTION OF MK-462 IN HEALTHY MALES

MK-677, an Orally Active Growth Hormone Secretagogue, Reverses Diet-Induced Catabolism1

Pharmacokinetics of extended release diltiazem in elderly subjects

Prospects for human gene therapy

Molecular cloning and nucleotide sequence of cDNA encoding a functional murine low-density-lipoprotein receptor

Prolonged fenoldopam infusions in patients with mild to moderate hypertension: Pharmacodynamic and pharmacokinetic effects

Two-Month Treatment of Obese Subjects with the Oral Growth Hormone (GH) Secretagogue MK-677 Increases GH Secretion, Fat-Free Mass, and Energy Expenditure1

Two-Month Treatment of Obese Subjects with the Oral Growth Hormone (GH) Secretagogue MK-677 Increases GH Secretion, Fat-Free Mass, and Energy Expenditure 1

Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers

Initial human experience with MK-462 (rizatriptan) : a novel 5-HT ID agonist

Reformulations Must Provide Added Value: Novel Drugs Must Really Improve on the Original; Dosing Convenience Alone Is Not Enough

D5Effect Of Food On The Pharmacokinetics Of Extended Release Diltiazem

D4Pharmacokinetics Of Extended Release Diltiazem In Elderly Subjects

Effect of food on the pharmacokinetics of extended release diltiazem

Improved protein analysis on nitrocellulose membranes

Suchergebnisse filtern